Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors

Abstract

Introduction In consonance with current the World Health Organization (WHO) classification of the central nervous system (CNS) tumors (2016), histological diagnosis of gliomas should be reinforced by molecular information. This study was performed to determine the frequency of isocitrate dehydrogenase 1 (IDH1), α thalassemia/intellectual disability syndrome X-linked (ATRX), p53, and BRAF V600E mutations in different grade astrocytomas and oligodendrogliomas.

Methods Seventy-seven cases of astrocytoma and oligodendroglioma (7 pilocytic astrocytomas, 15 diffuse astrocytomas [DA], 4 anaplastic astrocytomas [AA], 29 glioblastomas [GBM], and 22 oligodendrogliomas) were analyzed using immunohistochemistry for IDH1 mutant protein, ATRX, p53, and BRAF as well as their clinicopathological features assessed.

Results All pilocytic astrocytoma and primary glioblastoma cases were negative for an IDH1 mutation. IDH1 mutation was detected in 66.7% (10/15) of DA, 50% (2/4) of AA, 20.7% (6/29) of glioblastomas, and 81.8% (18/22) of oligodendroglioma cases. Loss of nuclear ATRX expression was found in 86.7% (13/15), 75% (3/4), and 34.5% (10/29) of DA, AA, and GBM cases, respectively. All oligodendroglioma cases showed retained ATRX expression. Both markers were found statistically significant in the above tumors (p <0.05). BRAF V600E mutation was detected in a single case of pilocytic astrocytoma and pleomorphic xanthoastrocytoma as well as both cases of epithelioid glioblastoma.

Conclusions IDH1 and ATRX mutations are very common in diffuse astrocytoma and anaplastic astrocytoma, while they are rare in pilocytic astrocytoma and glioblastoma. Immunohistochemistry for IDH1 and ATRX can successfully characterize the diffuse gliomas into molecularly defined groups in the majority of the cases. BRAF V600E mutation is rare in astrocytic tumors in the Indian population.

Keywords

astrocytoma - oligodendroglioma - glioblastoma - isocitrate - dehydrogenase

Ethical Approval Statement

Ethical approval had been taken from Institutional Ethics Committee with IEC no. 299/MC/EC/2020; dated 06/06/20.

Authors' Contribution

All the authors have read & approved the manuscript.

Publikationsverlauf

Artikel online veröffentlicht:
08. Juni 2022

• References

• 1 McNeill KA. Epidemiology of brain tumors. Neurol Clin 2016; 34 (04) 981-998
• 2 Ostrom QT, Gittleman H, Xu J. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-oncol 2016; 18 (suppl_5): v1-v75
• 3 McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7 (02) 418-419
• 4 Louis DN, Ohgaki H, Wiestler OD. et al; International Agency for Research on Cancer (IARC). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (02) 97-109
• 5 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. 4th rev. ed.. Lyon: IARC Press; 2016
• 6 Jha P, Suri V, Sharma V. et al. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol 2011; 91 (01) 385-393
• 7 Rajeswarie RT, Rao S, Nandeesh BN, Yasha TC, Santosh V. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. J Clin Pathol 2017; 71 (01) 323-329
• 8 Thota B, Shukla SK, Srividya MR. et al. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. Am J Clin Pathol 2012; 138 (02) 177-184
• 9 Li QJ, Cai JQ, Liu CY. Evolving molecular genetics of glioblastoma. Chin Med J (Engl) 2016; 129 (04) 464-471
• 10 Santosh V, Sravya P, Gupta T. et al. ISNO consensus guidelines for practical adaptation of the WHO 2016 classification of adult diffuse gliomas. Neurol India 2019; 67 (01) 173-182
• 11 Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2 (09) 533-543
• 12 Jazayeri SB, Rahimi-Movaghar V, Shokraneh F, Saadat S, Ramezani R. Epidemiology of primary CNS tumors in Iran: a systematic review. Asian Pac J Cancer Prev 2013; 14 (06) 3979-3985
• 13 Chatterjee D, Radotra BD, Kumar N, Vasishta RK, Gupta SK. IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. Surg Neurol Int 2018; 9: 29
• 14 Sumathi V, Balakrishnan K, Krishna MSS, Maheshwari KU. Histopathological spectrum and grading of CNS tumours in tertiary centre: Case study of 83 cases. J Evid Based Med Healthcare 2016; 3: 2240-2243
• 15 Hamdani SM, Dar NQ, Reshi R. Histopathological spectrum of brain tumors: a 4-year retrospective study from a single tertiary care facility. Int J Med Sci Public Health 2019; 8: 673-676
• 16 Dhar A, Bhat AR, Nizami FA. et al. Analysis of brain tumors in Kashmir Valley - A 10 year study. Bangladesh J Med Sci 2014; 13: 268-277
• 17 Ghanghoria S, Mehar R, Kulkarni CV, Mittal M, Yadav A, Patidar H. Retrospective histological analysis of CNS tumors – A 5 year study. Int J Med Sci Public Health 2014; 3: 1205-1207
• 18 Ahmed Z, Muzaffar S, Kayani N, Pervez S, Husainy AS, Hasan SH. Histological pattern of central nervous system neoplasms. J Pak Med Assoc 2001; 51 (04) 154-157
• 19 Ichimura K, Pearson DM, Kocialkowski S. et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncol 2009; 11 (04) 341-347
• 20 Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174 (04) 1149-1153
• 21 Zou P, Xu H, Chen P. et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One 2013; 8 (07) e68782
• 22 Cai J, Zhu P, Zhang C. et al. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget 2016; 7 (13) 16384-16395
• 23 Cai J, Zhang C, Zhang W. et al. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience 2016; 3 (7-8): 258-265
• 24 Jiao Y, Killela PJ, Reitman ZJ. et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3 (07) 709-722
• 25 Wiestler B, Capper D, Holland-Letz T. et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013; 126 (03) 443-451
• 26 Gillet E, Alentorn A, Doukouré B. et al. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol 2014; 118 (01) 131-139
• 27 Appin CL, Brat DJ. Molecular genetics of gliomas. Cancer J 2014; 20 (01) 66-72
• 28 Ellison D, Kleinschmidt-DeMasters B, Park SH. Epithelioid glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. eds. WHO Classification of Tumors of the Central Nervous System, Revised 4t. France: International Agency for Research on Cancer (IARC); 2016. 50,51
• 29 Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH. Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 2012; 5 (06) 430-436